Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 785

1.

Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature. 2001. 410: 1107-1111.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.

J Immunol. 2018 Aug 1;201(3):827-831. No abstract available.

2.

Distinct Biological Potential of Streptococcus gordonii and Streptococcus sanguinis Revealed by Comparative Genome Analysis.

Zheng W, Tan MF, Old LA, Paterson IC, Jakubovics NS, Choo SW.

Sci Rep. 2017 Jun 7;7(1):2949. doi: 10.1038/s41598-017-02399-4.

3.

StreptoBase: An Oral Streptococcus mitis Group Genomic Resource and Analysis Platform.

Zheng W, Tan TK, Paterson IC, Mutha NV, Siow CC, Tan SY, Old LA, Jakubovics NS, Choo SW.

PLoS One. 2016 May 3;11(5):e0151908. doi: 10.1371/journal.pone.0151908. eCollection 2016.

4.

Reinhard Hohlfeld: the neurologist with the magic touch.

Old L.

Lancet Neurol. 2016 Feb;15(2):140. doi: 10.1016/S1474-4422(15)00397-X. Epub 2016 Jan 12. No abstract available.

PMID:
28463121
5.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

6.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

7.

NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.

Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V.

Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14.

8.

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.

9.

The human cell surfaceome of breast tumors.

da Cunha JP, Galante PA, de Souza JE, Pieprzyk M, Carraro DM, Old LJ, Camargo AA, de Souza SJ.

Biomed Res Int. 2013;2013:976816. doi: 10.1155/2013/976816. Epub 2013 Sep 9.

10.

Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.

Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S.

Clin Cancer Res. 2013 Nov 15;19(22):6112-25. doi: 10.1158/1078-0432.CCR-12-3580. Epub 2013 Sep 30.

11.

Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials.

Bardliving CL, Lowe AJ, Huang CJ, Manley L, Ritter G, Old L, Batt CA.

Protein Expr Purif. 2013 Dec;92(2):171-82. doi: 10.1016/j.pep.2013.09.002. Epub 2013 Sep 15.

PMID:
24045055
12.

Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.

Lopes dos Santos M, Yeda FP, Tsuruta LR, Horta BB, Pimenta AA Jr, Degaki TL, Soares IC, Tuma MC, Okamoto OK, Alves VA, Old LJ, Ritter G, Moro AM.

PLoS One. 2013 Jul 31;8(7):e70332. doi: 10.1371/journal.pone.0070332. Print 2013.

13.

NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.

von Boehmer L, Mattle M, Bode P, Landshammer A, Schäfer C, Nuber N, Ritter G, Old L, Moch H, Schäfer N, Jäger E, Knuth A, van den Broek M.

Cancer Immun. 2013 Jul 15;13:12. Print 2013.

14.

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G.

Sarcoma. 2013;2013:168145. doi: 10.1155/2013/168145. Epub 2013 Feb 27.

15.

Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.

Hirayama M, Nishikawa H, Nagata Y, Tsuji T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjatic S, Shiku H.

Eur J Immunol. 2013 Apr;43(4):989-1000. doi: 10.1002/eji.201242800. Epub 2013 Feb 26.

16.

A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.

Gupta A, Nuber N, Esslinger C, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, van den Broek M.

Cancer Immun. 2013;13:3. Epub 2013 Jan 15.

17.

MAGE-A3 is highly expressed in a subset of colorectal cancer patients.

Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL.

Cancer Immun. 2012;12:16. Epub 2012 Dec 28.

18.

SurfaceomeDB: a cancer-orientated database for genes encoding cell surface proteins.

de Souza JE, Galante PA, de Almeida RV, da Cunha JP, Ohara DT, Ohno-Machado L, Old LJ, de Souza SJ.

Cancer Immun. 2012;12:15. Epub 2012 Dec 28.

19.

Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.

Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM.

Mol Imaging. 2013 Jan-Feb;12(1):67-73.

PMID:
23348793
20.

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S.

Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2.

21.

KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer.

Song MH, Ha JM, Shin DH, Lee CH, Old L, Lee SY.

Int J Oncol. 2012 Nov;41(5):1820-6. doi: 10.3892/ijo.2012.1601. Epub 2012 Aug 22.

PMID:
22923163
22.

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD.

Invest New Drugs. 2013 Apr;31(2):425-34. doi: 10.1007/s10637-012-9862-2. Epub 2012 Aug 5.

23.

Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity.

Karbach J, Neumann A, Brand K, Wahle C, Siegel E, Maeurer M, Ritter E, Tsuji T, Gnjatic S, Old LJ, Ritter G, Jäger E.

Clin Cancer Res. 2012 Oct 1;18(19):5449-59. doi: 10.1158/1078-0432.CCR-12-1116. Epub 2012 Jul 30.

24.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

25.

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation.

Kim KM, Song MH, Kim MJ, Daudi S, Miliotto A, Old L, Odunsi K, Lee SY.

Int J Oncol. 2012 Sep;41(3):1139-47. doi: 10.3892/ijo.2012.1508. Epub 2012 Jun 6.

26.

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jäger E.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802. doi: 10.1073/pnas.1117208109. Epub 2012 Mar 27.

27.

Antibody therapy of cancer.

Scott AM, Wolchok JD, Old LJ.

Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236. Review.

PMID:
22437872
28.

Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.

Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S.

J Immunol. 2012 Apr 15;188(8):3851-8. doi: 10.4049/jimmunol.1103269. Epub 2012 Mar 16.

29.

Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.

Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S.

Blood. 2012 Mar 29;119(13):3097-104. doi: 10.1182/blood-2011-09-379982. Epub 2012 Feb 8.

30.

Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.

Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S, Old LJ, Shiku H, Nishikawa H.

Cancer Res. 2012 Apr 1;72(7):1672-82. doi: 10.1158/0008-5472.CAN-11-3072. Epub 2012 Feb 8.

31.

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD.

Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755.

32.

Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.

Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM.

J Nucl Med. 2012 Feb;53(2):281-6. doi: 10.2967/jnumed.111.092973. Epub 2012 Jan 6.

33.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

34.

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.

Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G.

Br J Cancer. 2012 Jan 17;106(2):324-32. doi: 10.1038/bjc.2011.524. Epub 2011 Dec 1.

35.

Trypanosoma cruzi as an effective cancer antigen delivery vector.

Junqueira C, Santos LI, Galvão-Filho B, Teixeira SM, Rodrigues FG, DaRocha WD, Chiari E, Jungbluth AA, Ritter G, Gnjatic S, Old LJ, Gazzinelli RT.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19695-700. doi: 10.1073/pnas.1110030108. Epub 2011 Nov 23.

36.

Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.

Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E.

Int J Cancer. 2012 Sep 1;131(5):E649-58. doi: 10.1002/ijc.27359. Epub 2012 Jan 3.

37.

124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM.

J Nucl Med. 2011 Dec;52(12):1878-85. doi: 10.2967/jnumed.111.095596. Epub 2011 Nov 8.

38.

Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma.

Chen YT, Chiu R, Lee P, Beneck D, Jin B, Old LJ.

Hum Reprod. 2011 Dec;26(12):3232-43. doi: 10.1093/humrep/der330. Epub 2011 Oct 20.

PMID:
22016418
39.

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8. doi: 10.1073/pnas.1110814108. Epub 2011 Sep 20.

40.

Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.

Tsuji T, Matsuzaki J, Ritter E, Miliotto A, Ritter G, Odunsi K, Old LJ, Gnjatic S.

PLoS One. 2011;6(8):e23651. doi: 10.1371/journal.pone.0023651. Epub 2011 Aug 12.

41.

(124)I-huA33 antibody PET of colorectal cancer.

Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM.

J Nucl Med. 2011 Aug;52(8):1173-80. doi: 10.2967/jnumed.110.086165. Epub 2011 Jul 15.

42.

MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.

von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ.

PLoS One. 2011;6(7):e21366. doi: 10.1371/journal.pone.0021366. Epub 2011 Jul 6.

43.

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J.

Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23.

PMID:
21698545
44.

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, Cho HJ.

Clin Cancer Res. 2011 Jul 1;17(13):4309-19. doi: 10.1158/1078-0432.CCR-10-1820. Epub 2011 May 12.

45.

Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues.

Nissan A, Stojadinovic A, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc BE, Ritter G, Gomceli I, Bostanci EB, Akoglu M, Chen YT, Old LJ, Gure AO.

Int J Cancer. 2012 Apr 1;130(7):1598-606. doi: 10.1002/ijc.26170. Epub 2011 Aug 2.

46.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Review.

47.

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.

Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E.

Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29.

48.

Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.

Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM.

PLoS One. 2011 Mar 18;6(3):e17876. doi: 10.1371/journal.pone.0017876.

49.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Schreiber RD, Old LJ, Smyth MJ.

Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486. Review.

PMID:
21436444
50.

Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.

Pryma DA, O'Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR.

J Nucl Med. 2011 Apr;52(4):535-40. doi: 10.2967/jnumed.110.083295. Epub 2011 Mar 18.

Supplemental Content

Support Center